Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy

Pfizer had sponsored a phase 1/2 clinical trial to test the safety and the benefit of treating patients with LGMD2I. The LGMD2I program was an extension of an ongoing program in Duchenne Muscular Dystrophy (DMD). On August 30, Pfizer announced the termination of the Phase 2 safety and efficacy study and the open-label extension study because results of the Phase 2 safety and efficacy study did not show efficacy as measured by the 4-Stair Climb test after one year of treatment. Press Release